Literature DB >> 14597758

The TRAIL to arthritis.

George C Tsokos1, Maria Tsokos.   

Abstract

Antigen-specific lymphocytes are involved in synovial proliferation within inflamed joints. Activated lymphocytes and synoviocytes from patients with rheumatoid arthritis express receptors that can bind TNF-related apoptosis-inducing ligand (TRAIL). A new study demonstrates that DCs pulsed with collagen and transduced with an adenovirus-based vector able to express TRAIL limit the incidence of arthritis in a model of collagen-induced arthritis and joint inflammation. These results suggest that gene-modified cell therapy represents a therapeutic option for systemic rheumatic diseases.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14597758      PMCID： PMC228491          DOI： 10.1172/JCI20297

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  21 in total

1.  Gene therapy in the treatment of autoimmune diseases.

Authors:  G C Tsokos; G T Nepom
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy.

Authors:  Mark K Slifka; Joseph N Blattman; David J D Sourdive; Fei Liu; Donald L Huffman; Tom Wolfe; Anna Hughes; Michael B A Oldstone; Rafi Ahmed; Matthias G Von Herrath
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

3.  Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

Authors:  P Blanco; A K Palucka; M Gill; V Pascual; J Banchereau
Journal:  Science       Date:  2001-11-16       Impact factor: 47.728

4.  Anti-CD95-induced lethality requires radioresistant Fcgamma RII+ cells. A novel mechanism for fulminant hepatic failure.

Authors:  Satoshi Jodo; John T Kung; Sheng Xiao; Derek V Chan; Seiichi Kobayashi; Masatoshi Tateno; Robert Lafyatis; Shyr-Te Ju
Journal:  J Biol Chem       Date:  2002-12-10       Impact factor: 5.157

5.  Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.

Authors:  Hajime Higuchi; Steven F Bronk; Makiko Taniai; Ali Canbay; Gregory J Gores
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

6.  Antisense cyclic adenosine 5'-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus.

Authors:  Klaus Tenbrock; Yuang-Taung Juang; Mark F Gourley; Madhusoodana P Nambiar; George C Tsokos
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

7.  Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.

Authors:  N Mitsiades; V Poulaki; C Mitsiades; M Tsokos
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

8.  CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis.

Authors:  Zhongyu Liu; Xin Xu; Hui-Chen Hsu; Albert Tousson; Ping-Ar Yang; Qi Wu; Cunren Liu; Shaohua Yu; Huang-Ge Zhang; John D Mountz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

9.  Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis.

Authors:  Maryam Feili-Hariri; Dewayne H Falkner; Andrea Gambotto; Glenn D Papworth; Simon C Watkins; Paul D Robbins; Penelope A Morel
Journal:  Hum Gene Ther       Date:  2003-01-01       Impact factor: 5.695

10.  Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.

Authors:  K Song; Y Chen; R Göke; A Wilmen; C Seidel; A Göke; B Hilliard; Y Chen
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307
View more
  3 in total

1.  Apigenin enhances the cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand in human rheumatoid arthritis fibroblast-like synoviocytes.

Authors:  Qing-Wen Sun; Song-Min Jiang; Ke Yang; Jian-Ming Zheng; Li Zhang; Wei-Dong Xu
Journal:  Mol Biol Rep       Date:  2011-12-22       Impact factor: 2.316

2.  TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.

Authors:  Atil Bisgin; Ender Terzioglu; Cigdem Aydin; Burcak Yoldas; Veli Yazisiz; Nilufer Balci; Huseyin Bagci; Reginald M Gorczynski; Cezmi A Akdis; Salih Sanlioglu
Journal:  BMC Musculoskelet Disord       Date:  2010-08-27       Impact factor: 2.362

3.  Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.

Authors:  Arzu Didem Yalcin; Saadet Gumuslu; Gizem Esra Parlak; Atil Bısgın
Journal:  Med Sci Monit       Date:  2012-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.